Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer With Poor Response to First-Line Chemotherapy

NCT07637851 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT07637851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07637851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer With Poor Response to First-Line Chemotherapy
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
April 30, 2030
Enrollment
43 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer